Lung adenocarcinoma

Molecular-Based Decision Making for Personalized Cancer Management

Volumn , Issue , 2012, Pages 136-165

  Rosell, Rafael ^a,b,c,d,e   Botero, Maria Luisa ^b   Bivona, Trever ^b   Mendez, Pedro ^b   Cardona, Andres Felipe ^b   Campelo, Rosario Garcia ^b   Majem, Margarita ^b   Carcereny, Enric ^b   Viteri, Santiago ^b   Gascó, Amaya ^b   Buges, Cristina ^b   Moran, Teresa ^b   Santarpia, Mariacarmela ^b   Molina, Miquel Angel ^b   Romero, Laura ^b   Salazar, Fernanda ^b   Ramirez, Jose Luis ^b   Queralt, Cristina ^b   Bertran Alamillo, Jordi ^b   Chaib, Imane ^b   Costa, Carlota ^b   Benlloch, Susana ^b   Vergnenegre, Alain ^b   Garrido, Pilar ^b   Camps, Carlos ^b   Provencio, Mariano ^b   Sanchez, Jose Miquel ^b   De Castro, Javier ^b   Massuti, Bartomeu ^b   more..

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b Pangaea Biotech   (Spain)

^c INSTITUT UNIVERSITARI DEXEUS   (Spain)

^d University of Barcelona ^*  (Spain)

^e UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84961296307     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2217/EBO.12.11     Document Type: Chapter

References (95)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011).
2. Aberle DR, Adams AM, Berg CD et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 365(5), 395-409 (2011).
3. Heleno B, Rasmussen JF, Brodersen J. Reduced lungcancer mortality with CT screening. N. Engl. J. Med. 365(21), 2035-2038 (2011).
4. Bach PB. Reduced lung-cancer mortality with CT screening. N. Engl. J. Med. 365(21), 2035-2038 (2011).
5. Kohn MA. Reduced lungcancer mortality with CT screening. N. Engl. J. Med. 365(21), 2035-2038 (2011).
6. Oken MM, Hocking WG, Kvale PA et al. Screening by chest radiograph and lung cancer mortality: the prostate, lung, colorectal, and ovarian (PLCO) randomized trial. JAMA 306(17), 1865-1873 (2011).
7. Wei Q, Cheng L, Hong WK, Spitz MR. Reduced DNA repair capacity in lung cancer patients. Cancer Res. 56(18), 4103-4107 (1996).
8. Wang LE, Yin M, Dong Q et al. DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy. J. Clin. Oncol. 29(31), 4121-4128 (2011).
9. Bosken CH, Wei Q, Amos CI, Spitz MR. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J. Natl Cancer Inst. 94(14), 1091-1099 (2002).
10. Zeng-Rong N, Paterson J, Alpert L, Tsao MS, Viallet J, Alaoui-Jamali MA. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy. Cancer Res. 55(21), 4760-4764 (1995).
11. Van De Vaart PJ, Belderbos J, De Jong D et al. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int. J. Cancer 89(2), 160-166 (2000).
12. Schaake-Koning C, Van Den Bogaert W, Dalesio O et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N. Engl. J. Med. 326(8), 524-530 (1992).
13. Mendez P, Taron M, Moran T, Fernandez MA, Requena G, Rosell R. A modified host-cell reactivation assay to quantify DNA repair capacity in cryopreserved peripheral lymphocytes. DNA Repair (Amst.) 10(6), 603-610 (2011).
14. Mendez P, Taron M, Moran T et al. Feasibility of a prospective host cell reactivation assay (HCRA) in non-small cell lung cancer (NSCLC) patients. J. Clin. Oncol. 28(Suppl.), (2010) (Abstract 10586).
15. Fenech M. Biomarkers of genetic damage for cancer epidemiology. Toxicology 181-182, 411-416 (2002).
16. Rothfuss A, Schutz P, Bochum S et al. Induced micronucleus frequencies in peripheral lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families. Cancer Res. 60(2), 390-394 (2000).
17. El-Zein RA, Schabath MB, Etzel CJ, Lopez MS, Franklin JD, Spitz MR. Cytokinesisblocked micronucleus assay as a novel biomarker for lung cancer risk. Cancer Res. 66(12), 6449-6456 (2006).
18. Rosell R, Mendez P, Isla D, Taron M. Platinum resistance related to a functional NER pathway. J. Thorac. Oncol. 2(12), 1063-1066 (2007).
19. Zhou W, Gurubhagavatula S, Liu G et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin. Cancer Res. 10(15), 4939-4943 (2004).
20. Gurubhagavatula S, Liu G, Park S et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J. Clin. Oncol. 22(13), 2594-2601 (2004).
21. De Las Penas R, Sanchez-Ronco M, Alberola V et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann. Oncol. 17(4), 668-675 (2006).
22. Matullo G, Palli D, Peluso M et al. XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis 22(9), 1437-1445 (2001).
23. Wu X, Ye Y, Rosell R et al. Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J. Natl Cancer Inst. 103(10), 817-825 (2011).
24. Kim HT, Lee JE, Shin ES et al. Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy. J. Clin. Oncol. 26(36), 5972-5979 (2008).
25. Cobo M, Isla D, Massuti B et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a Phase III trial in non-small-cell lung cancer. J. Clin. Oncol. 25(19), 2747-2754 (2007).
26. Carcereny E, Ramirez JL, Sanchez-Ronco M et al. Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced nonsmall- cell lung cancer patients. Lung Cancer 68(3), 491-497 (2009).
27. Spitz MR, Gorlov IP, Amos CI et al. Variants in inflammation genes are implicated in risk of lung cancer in never smokers exposed to second-hand smoke. Cancer Discov. 0, 421-429 (2011).
28. Goldstraw P, Ball D, Jett JR et al. Non-small-cell lung cancer. Lancet 378, 1727-1740 (2011).
29. Goldstraw P, Crowley J, Chansky K et al. The IASLC lung cancer staging project:proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J. Thorac. Oncol. 2(8), 706-714 (2007).
30. Dillman RO, Seagren SL, Propert KJ et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-smallcell lung cancer. N. Engl. J. Med. 323(14), 940-945 (1990).
31. Fournel P, Robinet G, Thomas P et al. Randomized Phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J. Clin. Oncol. 23(25), 5910-5917 (2005).
32. Vokes EE, Herndon JE 2nd, Crawford J et al. Randomized Phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J. Clin. Oncol. 20(20), 4191-4198 (2002).
33. Curran WJ Jr, Paulus R, Langer CJ et al. Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer: randomized Phase III trial RTOG 9410. J. Natl Cancer Inst. 103(19), 1452-1460 (2011).
34. Quinn JE, Kennedy RD, Mullan PB et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res. 63(19), 6221-6228 (2003).
35. Taron M, Rosell R, Felip E et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum. Mol. Genet. 13(20), 2443-2449 (2004).
36. Roth JA, Fossella F, Komaki R et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA nonsmall- cell lung cancer. J. Natl Cancer Inst. 86(9), 673-680 (1994).
37. Rosell R, Gomez-Codina J, Camps C et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N. Engl. J. Med. 330(3), 153-158 (1994).
38. Van Meerbeeck JP, Kramer GWPM, Van Schil PEY et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J. Natl Cancer Inst. 99, 442-450 (2007).
39. Albain KS, Swann RS, Rusch VW et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a Phase III randomised controlled trial. Lancet 374(9687), 379-386 (2009).
40. Eberhardt W, Wilke H, Stamatis G et al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a Phase II trial. J. Clin. Oncol. 16(2), 622-634 (1998).
41. Weder W, Collaud S, Eberhardt WE et al. Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer. J. Thorac. Cardiovasc. Surg. 139(6), 1424-1430 (2010).
42. Rothschild SI, Gautschi O, Lara PN Jr, Mack PC, Gandara DR. Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer. Curr. Opin. Oncol. 23(2), 150-157 (2011).
43. Mcdermott U, Downing JR, Stratton MR. Genomics and the continuum of cancer care. N. Engl. J. Med. 364(4), 340-350 (2011).
44. Loeb LA. Human cancers express mutator phenotypes:origin, consequences and targeting. Nat. Rev. Cancer 11(6), 450-457 (2011).
45. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12(2), 175-180 (2011).
46. Lanuti M, Sequist LV, Sharma A, Mino-Kenudson M. Case records of the Massachusetts general hospital. Case 31-2011. A 55-year-old man with oligometastatic lung cancer. N. Engl. J. Med. 365(15), 1426-1435 (2011).
47. Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361(10), 958-967 (2009).
48. Arrieta O, Cardona AF, Federico Bramuglia G et al. Genotyping non-small cell lung cancer (NSCLC) in Latin America. J. Thorac. Oncol. 6(11), 1955-1959 (2011).
49. Pao W, Iafrate AJ, Su Z. Genetically informed lung cancer medicine. J. Pathol. (2010).
50. Xin H, Herrmann A, Reckamp K et al. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer Res. 71(21), 6601-6610 (2011).
51. Rosell R, Viteri S, Molina MA, Benlloch S, Taron M. Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer. Curr. Opin. Oncol. 22(2), 112-120 (2010).
52. Rosell R, Molina MA, Costa C et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinibtreated advanced non-smallcell lung cancer patients with EGFR mutations. Clin. Cancer Res. 17(5), 1160-1168 (2011).
53. Bivona TG, Hieronymus H, Parker J et al. FAS and NF-kB signalling modulate dependence of lung cancers on mutant EGFR. Nature 471(7339), 523-526 (2011).
54. Rosell R, Gervais R, Vergnenegre A et al. Erlotinib vs chemotherapy (CT) in advanced non-small-cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) activating mutations: interim results of the European Tarceva® vs Chemotherapy (EURTAC) Phase III randomized trial. J. Clin. Oncol. 29(Suppl.), (2011) (Abstract 7503).
55. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised Phase 3 trial. Lancet Oncol. 11(2), 121-128 (2010).
56. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-smallcell lung cancer with mutated EGFR. N. Engl. J. Med. 362(25), 2380-2388 (2010).
57. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947-957 (2009).
58. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutationpositive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, Phase 3 study. Lancet Oncol. 12, 735-742 (2011).
59. Travis WD, Brambilla E, Noguchi M et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J. Thorac. Oncol. 6(2), 244-285 (2011).
60. Rosell R, Perez-Roca L, Sanchez JJ et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS ONE 4(5), E5133 (2009).
61. Molina-Vila MA, Bertran-Alamillo J, Reguart N et al. A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells. J. Thorac. Oncol. 3(11), 1224-1235 (2008).
62. Inukai M, Toyooka S, Ito S et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res. 66(16), 7854-7858 (2006).
63. Maheswaran S, Sequist LV, Nagrath S et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359(4), 366-377 (2008).
64. Sethi G, Ahn KS, Chaturvedi MM, Aggarwal BB. Epidermal growth factor (EGF) activates nuclear factor-kB through IkBa kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of IkBa. Oncogene 26(52), 7324-7332 (2007).
65. Bredel M, Scholtens DM, Yadav AK et al. NFKBIA deletion in glioblastomas. N. Engl. J. Med. 364(7), 627-637 (2011).
66. Santarpia M, Magri I, Sanchez-Ronco M et al. mRNA expression levels and genetic status of genes involved in the EGFR and NF-kB pathways in metastatic non-small-cell lung cancer patients. J. Transl. Med. 9, 163 (2011).
67. Sequist LV, Waltman BA, Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3(75), 75ra26 (2011).
68. Marchetti A, Felicioni L, Malatesta S et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J. Clin. Oncol. 29(26), 3574-3579 (2011).
69. Yu J, Zhang SS, Saito K et al. PTEN regulation by Akt-EGR1-ARF-PTEN axis. EMBO J. 28(1), 21-33 (2009).
70. Yamamoto C, Basaki Y, Kawahara A et al. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Res. 70(21), 8715-8725 (2010).
71. Faber AC, Corcoran RB, Hiromichi E et al. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors Cancer Discov. 1 (4), 352-365 (2011).
72. Costa DB, Halmos B, Kumar A et al. BIM mediates EGFR tyrosine kinase inhibitorinduced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 4(10), 1669-1679 (2007).
73. Guo D, Reinitz F, Youssef M et al. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLRdependent pathway. Cancer Discov. 1(5), 442-456 (2011).
74. Schaffer BE, Park KS, Yiu G et al. Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. Cancer Res. 70(10), 3877-3883 (2010).
75. Arcila ME, Oxnard GR, Nafa K et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin. Cancer Res. 17(5), 1169-1180 (2011).
76. Chmielecki J, Foo J, Oxnard GR et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci. Transl. Med. 3(90), 90ra59 (2011).
77. Chaft JE, Oxnard GR, Sima CS, Miller VA, Kris MG, Riely GJ. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib. Clin. Cancer Res. (2011).
78. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7(3), 169-181 (2007).
79. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-smallcell lung cancer. Nat. Rev. Cancer 10(11), 760-774 (2010).
80. Rho JK, Choi YJ, Jeon BS et al. Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation. Mol. Cancer Ther. 9(12), 3233-3243 (2010).
81. Ware KE, Marshall ME, Heasley LR et al. Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. PLoS ONE 5(11), E14117 (2010).
82. Zhong D, Liu X, Khuri FR, Sun SY, Vertino PM, Zhou W. LKB1 is necessary for Akt-mediated phosphorylation of proapoptotic proteins. Cancer Res. 68(18), 7270-7277 (2008).
83. Rosell R, Cecere F, Santarpia M, Reguart N, Taron M. Predicting the outcome of chemotherapy for lung cancer. Curr. Opin. Pharmacol. (2006).
84. Lecharpentier A, Vielh P, Perez-Moreno P, Planchard D, Soria JC, Farace F. Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. Br. J. Cancer 105(9), 1338-1341 (2011).
85. Shintani Y, Okimura A, Sato K et al. Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in nonsmall cell lung cancer. Ann. Thorac. Surg. 92(5), 1794-1804 (2011).
86. Guo A, Villen J, Kornhauser J et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc. Natl Acad. Sci. USA 105(2), 692-697 (2008).
87. Stommel JM, Kimmelman AC, Ying H et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318(5848), 287-290 (2007).
88. Muller-Tidow C, Diederichs S, Bulk E et al. Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. Cancer Res. 65(5), 1778-1782 (2005).
89. Rikova K, Guo A, Zeng Q et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131(6), 1190-1203 (2007).
90. Turke AB, Zejnullahu K, Wu YL et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17(1), 77-88 (2010).
91. Wimmel A, Glitz D, Kraus A, Roeder J, Schuermann M. Axl receptor tyrosine kinase expression in human lung cancer cell lines correlates with cellular adhesion. Eur. J. Cancer 37(17), 2264-2274 (2001).
92. Gjerdrum C, Tiron C, Hoiby T et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc. Natl Acad. Sci. USA 107(3), 1124-1129 (2010).
93. Thomson S, Petti F, Sujka-Kwok I, Epstein D, Haley JD. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin. Exp. Metastasis 25(8), 843-854 (2008).
94. Marek L, Ware KE, Fritzsche A et al. Fibroblast growth factor (FGF) and FGF receptormediated autocrine signaling in non-small-cell lung cancer cells. Mol. Pharmacol. 75(1), 196-207 (2009).
95. Kono SA, Marshall ME, Ware KE, Heasley LE. The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resist Updat 12(4-5), 95-102 (2009).